Eli Lilly Overview

  • Founded
  • 1876
Founded
  • Status
  • Public
  • Employees
  • 33,625
Employees
  • Stock Symbol
  • LLY
Stock Symbol
  • Investments
  • 92
  • Share Price
  • $202.35
  • (As of Thursday Closing)

Eli Lilly General Information

Description

Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact Information

Website
lilly.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NYS
Primary Office
  • Lilly Corporate Center
  • Indianapolis, IN 46285
  • United States
+1 (317) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eli Lilly Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$202.35 $201.26 $117.06 - $204.72 $194B 957M 4.55M $6.15

Eli Lilly Financials Summary

In Thousands,
USD 		TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 155,696,144 140,327,287 127,299,871 99,590,359
Revenue 23,213,800 22,319,500 21,493,300 19,973,800
EBITDA 8,046,900 6,818,700 5,372,300 3,930,700
Net Income 5,572,600 8,318,400 3,232,000 (204,100)
Total Assets 43,946,000 39,286,100 43,908,400 44,981,000
Total Debt 16,922,100 15,803,900 10,298,600 13,647,100
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eli Lilly Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eli Lilly‘s full profile, request access.

Request a free trial

Eli Lilly Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products
Drug Discovery
Indianapolis, IN
33,625 As of 2019
000000 - 000

000000 0

it in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
0000000000000
Foster City, CA
00000 As of 0000
00.000
000000&0

000000

d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000 000000000
Cambridge, MA
0000 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eli Lilly Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gilead Sciences Formerly VC-backed Foster City, CA 00000 00.000 000000&0
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
00000 & 00. Corporation Kenilworth, NJ 00000 00000000
000000 Formerly VC-backed North Chicago, IL 00000 00000000000
00000000000 000000 Private Equity-Backed Mexico City, Mexico 000.00 0000000 0000
You’re viewing 5 of 11 competitors. Get the full list »

Eli Lilly Executive Team (71)

Name Title Board Seat Contact Info
David Ricks Chief Executive Officer and Chairman of the Board
Daniel Skovronsky Ph.D Chief Scientific Officer & President
Patrik Jonsson President of Lilly USA, Senior Vice President & Chief Customer Officer
Myles O'Neill Senior Vice President and President, Manufacturing Operations
Joshua Smiley Senior Vice President and Chief Financial Officer
You’re viewing 5 of 71 executive team members. Get the full list »

Eli Lilly Board Members (15)

Name Representing Role Since
00000 00000 Eli Lilly Chief Executive Officer and Chairman of the Board 000 0000
00000 000000 Self Chairman, Directors and Corporate Governance Committee 000 0000
000000000 0000000000 00 Self Board Member 000 0000
0. 0000000 Self Board Member 000 0000
0000000 000 Self Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Eli Lilly Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eli Lilly Investments & Acquisitions (92)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 0000000 08-Jan-2021 0000 00000 Drug Discovery
00000 000000000000 05-Jan-2021 00000 00000 00 0000 Drug Discovery
0000000 0000000000 15-Dec-2020 000000000000000000 00.000 Biotechnology 0000 000000
0000 000000000 10-Dec-2020 00000 00000 00 0000 Other Healthcare Services
Protomer Technologies 30-Nov-2020 Seed Round 00.00 Drug Delivery 0000 000000 00.0
You’re viewing 5 of 92 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Eli Lilly Subsidiaries (8)

Company Name Industry Location Founded
Loxo Oncology Acquirer Stamford, CT 2013
0000 00000000000 Biotechnology Redwood City, CA 0000
0000000 000000000 Biotechnology Montreal, Canada 0000
0000000 Pharmaceuticals Menlo Park, CA 0000
00000 0000 0000000 Venture Capital Shanghai, China 0000
You’re viewing 5 of 8 subsidiaries. Get the full list »

Eli Lilly Exits (28)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000 27-May-2020 00000 00000 00 00000 Completed
  • 8 buyers
00000000 13-Nov-2018 00000 00000 00 0000 Completed
  • 15 buyers
0000000 25-Jul-2018 00000 00000 00 00000 Completed
  • 20 buyers
0000000 19-Dec-2017 000000000 000 Completed
  • 000 00000
Leap Therapeutics 15-Nov-2017 PIPE 0000 Completed
You’re viewing 5 of 28 exits. Get the full list »